A new report from the National Audit Office has found that In 2017-18, 42% (87 of 207) of Clinical Commissioning Groups (CCGs) were rated either ‘requires improvement’ or ‘inadequate’, with as little as 10% rated as ‘outstanding’.Original Article
You may also like
Ariane de Ganck
Jasper Therapeutics merges with Kira Pharmaceuticals
Lilly to acquire AtaiBeckley in deal worth $2.8bn
Camena Bioscience appoints Gregory McGuinness as CEO
New €25 Million BioReliance Testing Facility Opens...
StockWatch: Lilly’s Up-to-$3.8B Deal for AtaiBeckley...
About the author
David Miller
a pharmacist, a tech enthusiastic, who explored the Internet to gather all latest information pharma, biotech, healthcare and other related industries.
